Inimmune Appoints New Chief Medical Officer and Head of Financial Strategy Ahead of Phase 2 Allergic Rhinitis Data
核心洞察
Inimmune Corporation (搜索) has appointed Ferdinand Massari, M.D., as Chief Medical Officer and Ryan McMillian as Head of Financial Strategy to strengthen leadership ahead of Phase 2 INI-2004 allergic rhinitis data readout.
Dr. Massari brings over two decades of clinical development experience in immunology and inflammatory diseases from companies including Shire, Pfizer, Pharmacia (搜索), and Merck (搜索).
The leadership appointments support Inimmune's strategic expansion of INI-2004 development into allergic asthma and food allergy, conditions affecting millions worldwide.
Inimmune Corporation (搜索) announced key leadership appointments on March 5, 2026, naming Ferdinand Massari, M.D., as Chief Medical Officer and Ryan McMillian as Head of Financial Strategy. The clinical-stage biotechnology company made these strategic hires as it prepares for Phase 2 data readout from its lead allergic rhinitis program, INI-2004, and plans expansion into allergic asthma and food allergy.
Strategic Leadership Expansion
"Inimmune is entering an important phase of growth as we continue to advance our pipeline and broaden our capabilities," said David Burkhart, Ph.D., Chief Executive Officer of Inimmune Corporation (搜索). "As we look ahead to upcoming clinical milestones, Dr. Massari's deep clinical development expertise and Mr. McMillian's financial leadership position us to execute with focus and discipline as we work to bring innovative immunotherapies to patients who urgently need better options."
New Chief Medical Officer Brings Extensive Experience
Dr. Massari joins Inimmune with more than two decades of experience in clinical development and translational medicine across immunology and inflammatory diseases. He has led high-performing clinical teams in both biotechnology and large pharmaceutical settings, having held senior clinical and medical leadership roles at Shire, Pfizer, Pharmacia (搜索), and Merck (搜索), where he supported the development and commercialization of therapies across multiple therapeutic areas.
As CMO, Dr. Massari will lead Inimmune's clinical strategy and execution, including continued development of INI-2004, the company's lead allergy program, and planned expansion into allergic asthma and food allergy. He succeeds Dr. Jon Ruckle, who successfully advanced Inimmune's oncology and allergy programs through Phase 1 clinical trials.
"The Phase 2 progress in allergic rhinitis underscores the potential of INI-2004 as a differentiated, disease-modifying therapy," said Dr. Massari. "I'm pleased to join Inimmune at this pivotal time and help advance the program into its next stage of clinical development."
Financial Strategy Leadership
Mr. McMillian brings more than 20 years of experience in biotech finance, corporate strategy, and capital formation, including more than $250 million in fundraising for life sciences companies. He previously served as Head of U.S. Finance at Alexion Pharmaceuticals, where he provided financial leadership and supported multiple orphan drug launches. He was also part of the investment and advisory ecosystem at Yale Ventures and held corporate finance and banking roles at GE Capital.
At Inimmune, Mr. McMillian will lead financial planning and strategic initiatives to support the company's expanding clinical portfolio and long-term growth strategy.
"Inimmune has built a compelling clinical foundation in allergic disease," said Mr. McMillian. "I look forward to helping the company execute its growth strategy, strengthen financial readiness, and support the advancement of therapies that have the potential to meaningfully improve patients' lives."
Pipeline Expansion Strategy
The new leadership appointments support Inimmune's strategic focus to expand development of its rapid, disease-modifying immunotherapy into allergic asthma and food allergy—conditions affecting millions worldwide and carrying a substantial clinical and economic burden.
Inimmune is a clinical-stage biotechnology company focused on the discovery and development of next-generation immunotherapies for the treatment of infectious diseases, allergy, and cancer. The company leverages proprietary technology platforms to create treatments that harness the immune system to improve patient outcomes.